AiViva was founded in 2015 by a group of four pharmaceutical industry veterans with more than 160 years of combined industry experience. AiViva's founders have demonstrated successful track records across the full spectrum of drug development and commercialization, in addition to successful fund raises and IPOs on the NYSE and NASDAQ.
AiViva was formed with the mission of developing novel, innovative drug products to address the challenges of difficult-to-treat conditions in therapeutic areas with unmet or underserved medical needs.
We are developing drug products with the potential to profoundly reduce the treatment burden for patients and physicians and which may transform current treatment paradigms in our areas of focus. Our approach leverages our proprietary JEL™ Technology to discover new clinical uses for existing drug substances, with established human safety and efficacy, to meaningfully differentiate them from existing therapies. AiViva has a diverse pipeline with multiple novel drug candidates in development in areas of dermatology, ophthalmology, oncology, and urology with the potential to expand to other areas of interest.